Lupin Limited — Updates, 26-06-2025: Press Release

Lupin has announced a board meeting to consider the financial results for the quarter and half-year. The company has launched Prucalopride Tablets (1 mg and 2 mg) in the U.S. following FDA ANDA approval. These tablets are bioequivalent to Takeda’s Motegrity®, which had annual sales of USD 184 million. This launch strengthens Lupin’s presence in the U.S. GI segment and has potential to contribute meaningfully to its U.S. revenue growth.